Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma.
about
Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network.Primary treatment response rather than front line stem cell transplantation is crucial for long term outcome of peripheral T-cell lymphomas.Comparison of survival in patients with T cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed disease.Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin.How I treat the peripheral T-cell lymphomasAdult systemic anaplastic large-cell lymphoma: recommendations for diagnosis and managementFirst-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation.Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015.X. Challenges and future directions in peripheral T-cell lymphoma.The role of alisertib in treatment of peripheral T-cell lymphomas.Investigational drugs for T-cell lymphoma.Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy.Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma.Mature T- and NK-cell non-Hodgkin lymphoma in children and young adolescents.How I manage peripheral T-cell lymphoma, not otherwise specified and angioimmunoblastic T-cell lymphoma: current practice and a glimpse into the future.Childhood, adolescent and young adult non-Hodgkin lymphoma: state of the science.Is myeloablative dose intensity necessary in allogeneic hematopoietic cell transplantation for lymphomas?Autologous stem cell transplantation as frontline strategy for peripheral T-cell lymphoma: A single-centre experienceT-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment.Treatment approaches of hard-to-treat non-Hodgkin lymphomas.Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells.ALK expression plays different roles in anaplastic large-cell lymphomas and outcome of crizotinib use in relapsed/refractory ALK+ patients in a Chinese population.Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma.The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers.A new prognostic score comprising lactate dehydrogenase, albumin and neutrophil to lymphocyte ratio to predict sensitivity to first-line chemotherapy in patients with peripheral T-cell lymphomas.Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study.Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma.Evaluation of clinical trial eligibility and prognostic indices in a population-based cohort of systemic peripheral T-cell lymphomas from the Danish Lymphoma Registry.A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.Outcome for patients with relapsed/refractory aggressive lymphoma treated with gemcitabine and oxaliplatin with or without rituximab; a retrospective, multicentre study.Second allo-SCT in patients with lymphoma relapse after a first allogeneic transplantation. A retrospective study of the EBMT Lymphoma Working Party.Successful use of brentuximab vedotin for refractory anaplastic large cell lymphoma as a bridging therapy to haploidentical stem cell transplantation and maintenance therapy post-transplantation.Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma.Imatinib mesylate lacks efficacy in relapsed/refractory peripheral T cell lymphoma.Peripheral T-cell Lymphomas: Updates in Allogeneic Hematopoietic Stem Cell TransplantationBrentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review
P2860
Q33423638-61281C15-15A2-44CA-991C-CAD04CCDA2EDQ34034389-31613F15-6D67-4D9E-8A69-99B775E40A48Q35224833-5C4EC95B-A69C-45CF-A9E3-DF6838C12F6EQ35533531-438675E7-1CD4-4F90-A2E7-1F7ED1EA051EQ35586880-31DDDDE0-D289-4132-BC1C-E58C7CD98E7CQ35865090-C3FC2D81-A511-42BF-867D-4A5508AE9C46Q36926529-CE5A9549-92C6-40DF-A0BE-0E3DF2E08731Q37271019-7E7B28D9-CF03-42CC-8AE7-60B644160231Q38387292-5D27511B-C4FF-4C6C-972C-A6E20BE42EBBQ38524000-8014AC09-7079-4EFD-B431-2A29879A6CFEQ38581916-652F9BFD-34E2-4E18-80B0-E19EA0DDD826Q38635909-F0832904-F927-464B-B6DA-C9F630A1F327Q38707852-2D11719F-0A59-4D7D-A08F-C10B689135D6Q38777460-3014140B-8245-42AC-9E15-26BE35E5EB00Q38780407-D5D81AE6-3E20-430A-AC8F-61CB9B326CA7Q38782072-BF841353-1987-42D1-A375-9BE6FFFA8A09Q38822525-ECCAD121-182A-4F95-97B3-31566E0D0F33Q38860997-F28E4025-FED9-411C-B7D0-B3D60226AA05Q38949798-0B07BB78-3ABD-429B-8E4E-AAE34E3DAE2AQ39063866-A7BB71BE-4C4C-4F4F-8406-FA30DA4756BEQ39091822-EB9986BC-EEDC-4357-A104-B3140078F0E7Q42009840-908787EA-8A7C-45F6-831B-B3AA21118CE2Q47575958-5DBA88F5-6997-4EEF-A1B1-D8B56EE95528Q47603352-8182AF6F-9C4B-4250-A3ED-197897F874EEQ48301800-3EDBFD07-0378-46B0-AC96-0F119462FDBBQ48365219-7CF6D870-EBA6-41C6-8137-8492ACC13B5CQ48650246-0C6D5978-30CA-4C0F-9C4E-81CA2BF801B7Q49435953-C381ABE6-9676-48CA-B20F-3B458D7454C2Q50562057-055E306B-DEAA-482E-BFEF-38A2EE079A6EQ52603856-B4656717-0850-4C43-94E5-BAD22B135D59Q52955130-42032DFB-3769-4DB9-AB68-FD13D87F1874Q52960823-36BFBCB5-2D03-4E4E-85F4-8E5186379A8DQ52970765-BDC7F3BB-195D-42EE-BDD7-EAE1EE47D520Q53060890-AC3443D5-B3C0-4FAD-BEAE-45111EBB6304Q54338742-BF995AE9-F501-4FF7-B973-3EB2820F0B10Q58763961-AD39BDD5-E621-4555-B9A1-BFC00C6AD78FQ58799247-126ACCBE-4BB3-4A7A-BDE1-E1E6A8986BAB
P2860
Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma.
@en
Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma.
@nl
type
label
Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma.
@en
Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma.
@nl
prefLabel
Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma.
@en
Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma.
@nl
P2093
P2860
P356
P1476
Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma.
@en
P2093
Anna Sureda
Cesar O Freytes
David J Inwards
Dipnarine Maharaj
Ginna G Laport
Gregory A Hale
Harry C Schouten
Jack W Hsu
Jennifer Lerademacher
Koen van Besien
P2860
P304
P356
10.1200/JCO.2012.46.0188
P407
P577
2013-07-29T00:00:00Z